Skip to main content
. 2021 Jan 20;13(3):372. doi: 10.3390/cancers13030372

Figure 3.

Figure 3

Drug repurposing screen identifies abemaciclib as an inhibitor of c-Met. (A) Overview of the drug repurposing screen. PDC6 were treated with 58 targeted agents and SAIT301, and image-based p-c-Met fluorescence assay was performed. (B) AUC was obtained from DRC of p-c-Met assay. Representative graph shows AUC of SAIT301 and four known c-Met-targeting inhibitors and three CDK4/6 inhibitors (****: p < 0.0001, ***: p < 0.001, **: p < 0.01, *: p ≤ 0.05, ns: p > 0.05, not significant). (C) Z-score of DMSO and 58 drugs for p-c-Met screen. (D) DRC of normalized p-c-Met intensity for SAIT301 (left) and abemaciclib (right). (E) Fluorescence images of DAPI (blue) and p-c-Met (green) in PDC6 treated with SAIT301(10 μg/mL), four known c-Met-targeting inhibitors (20 μm), and three CDK4/6 inhibitors (20 μm).